Marizomib Central Nervous System (CNS)

• Status: Not yet recruiting
• Trial end date: 2025-12-02

Summary

This research is being done to test whether the investigational drug marizomib is safe and effective when used in combination with standard of care drugs for the treatment of multiple myeloma.

• Phase: Phase 2

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Bristol-Myers Squibb
• Treatments: Dexamethasone; Pomalidomide